Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854393 | 0.88 | TLR7 (0.55) | TLR8TLR7 | |
| SCHEMBL28697055 | 0.88 | TLR7 (0.55) | TLR8TLR7 | |
| SCHEMBL29351456 | 0.88 | TLR7 (0.55) | TLR8TLR7 | |
| SCHEMBL20515185 | 0.86 | TLR8 (0.67) | TLR8TLR7 | |
| SCHEMBL28627809 | 0.86 | TLR8 (0.67) | TLR8TLR7 | |
| SCHEMBL2850299 | 0.81 | TLR7 (0.65) | TLR8TLR7 | |
| SCHEMBL2847749 | 0.81 | TLR7 (0.65) | TLR8TLR7 | |
| SCHEMBL2850753 | 0.79 | TLR7 (0.64) | TLR8TLR7 | |
| SCHEMBL2843476 | 0.79 | TLR7 (0.64) | TLR8TLR7 | |
| SCHEMBL2844596 | 0.78 | TLR7 (0.69) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11253476-B2 | Vaccine adjuvant formulation | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-02-22 | — | — | US | disclosed |
| US-20200121600-A1 | VACCINE ADJUVANT FORMULATION | Sumitomo Pharma Co., Ltd. (JP) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11253476-B2 | Vaccine adjuvant formulation | TLR7, TLR9, TLR5 | TLR8 4/4885TLR7 1/4885 |
| US-20200121600-A1 | VACCINE ADJUVANT FORMULATION | TLR7, TLR9, TLR5 | TLR8 4/4885TLR7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.